Globus Medical Inc GMED
We take great care to ensure that the data presented and summarized in this overview for GLOBUS MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMED
View all-
Vanguard Group Inc Valley Forge, PA10.6MShares$869 Million0.01% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$846 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07MShares$572 Million0.27% of portfolio
-
State Street Corp Boston, MA3.57MShares$292 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.6MShares$213 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA2.58MShares$211 Million0.03% of portfolio
-
Burgundy Asset Management Ltd. Toronto, A62.57MShares$211 Million1.91% of portfolio
-
Sculptor Capital LP New York, NY2.21MShares$181 Million5.72% of portfolio
-
Hawk Ridge Capital Management LP Los Angeles, CA2.18MShares$178 Million7.8% of portfolio
-
Camber Capital Management LP Boston, MA2.15MShares$176 Million4.89% of portfolio
Latest Institutional Activity in GMED
Top Purchases
Top Sells
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Insider Transactions at GMED
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$217,500
$87.0 P/Share
|
Dec 02
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$60,000
$24.21 P/Share
|
Nov 22
2024
|
David D Davidar |
SELL
Open market or private sale
|
Indirect |
6,746
-3.91%
|
$573,410
$85.0 P/Share
|
Nov 22
2024
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
6,766
-1.29%
|
$575,110
$85.0 P/Share
|
Nov 22
2024
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
1,097
-100.0%
|
$93,245
$85.02 P/Share
|
Nov 22
2024
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
1,097
+50.0%
|
$71,305
$65.05 P/Share
|
Nov 21
2024
|
David D Davidar |
SELL
Open market or private sale
|
Indirect |
13,254
-7.13%
|
$1,126,590
$85.0 P/Share
|
Nov 21
2024
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
13,234
-2.47%
|
$1,124,890
$85.0 P/Share
|
Nov 21
2024
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
13,278
-100.0%
|
$1,128,630
$85.0 P/Share
|
Nov 21
2024
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
13,278
+50.0%
|
$863,070
$65.05 P/Share
|
Nov 21
2024
|
Daniel T Scavilla President, CEO |
SELL
Open market or private sale
|
Direct |
130,000
-100.0%
|
$11,050,000
$85.0 P/Share
|
Nov 21
2024
|
Daniel T Scavilla President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+44.05%
|
$5,590,000
$43.68 P/Share
|
Nov 15
2024
|
David C Paul Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
26,042
+50.0%
|
$625,008
$24.1 P/Share
|
Nov 06
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
5,000
-75.0%
|
$405,000
$81.01 P/Share
|
Nov 06
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$120,000
$24.21 P/Share
|
Nov 06
2024
|
Daniel T Scavilla President, CEO |
SELL
Open market or private sale
|
Direct |
60,000
-100.0%
|
$4,800,000
$80.02 P/Share
|
Nov 06
2024
|
Daniel T Scavilla President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+41.67%
|
$2,100,000
$35.02 P/Share
|
Oct 16
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$562,500
$75.02 P/Share
|
Oct 16
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$187,500
$25.8 P/Share
|
Oct 16
2024
|
David D Davidar |
SELL
Open market or private sale
|
Indirect |
20,000
-9.71%
|
$1,500,000
$75.03 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 365K shares |
---|
Open market or private sale | 452K shares |
---|---|
Bona fide gift | 8K shares |